13 March 2023 - The blood thinner Eliquis from BMS, Pfizer's breast cancer drug Ibrance and AbbVie's leukaemia treatment Imbruvica are likely to be among 10 big selling medicines subject to US price negotiations for 2026, according to five Wall Street and academic analyses.

Last year Congress passed the Inflation Reduction Act, giving the U.S. Government power to start the first price negotiations over prescription drugs for its Medicare health program covering more than 60 million Americans, most over age 65.

Read Reuters article